Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Patients Treated With Alemtuzumab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT02205489
What this trial is testing

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Genzyme, a Sanofi Company 58
Testing effectiveness (Phase 2)Study completedNCT00006390
What this trial is testing

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Who this might be right for
Leukemia
Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)WithdrawnNCT00504491
What this trial is testing

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic LeukaemiaPatients Resistant to a Purine AnalogousPatients Relapsed With Purines Therapy
CABYC
Testing effectiveness (Phase 2)Ended earlyNCT02701517
What this trial is testing

Cyclosporine Plus Methotrexate or Alemtuzumab

Who this might be right for
Unrecognized Condition: Mature B or T-cell Neoplasm
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 72
Testing effectiveness (Phase 2)WithdrawnNCT00081068
What this trial is testing

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Temporarily pausedNCT01982175
What this trial is testing

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Who this might be right for
B-cell Chronic Lymphocytic Leukemia
Shanghai Zhangjiang Biotechnology Limited Company 120
Testing effectiveness (Phase 2)Study completedNCT00328198
What this trial is testing

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Who this might be right for
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Genzyme, a Sanofi Company 86
Early research (Phase 1)Study completedNCT03989466
What this trial is testing

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Who this might be right for
Recurrent T-Cell Prolymphocytic LeukemiaT-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT00669318
What this trial is testing

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Mayo Clinic 41
Testing effectiveness (Phase 2)Study completedNCT02385110
What this trial is testing

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)UnknownNCT00908180
What this trial is testing

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Lymphoma
Cancer Research UK 47
Testing effectiveness (Phase 2)Study completedNCT01186640
What this trial is testing

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Who this might be right for
T-cell-prolymphocytic Leukemia
German CLL Study Group 16
Testing effectiveness (Phase 2)Study completedNCT00274976
What this trial is testing

Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Who this might be right for
Leukemia
German CLL Study Group
Testing effectiveness (Phase 2)Study completedNCT00436904
What this trial is testing

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Who this might be right for
Leukemia
Mayo Clinic 30
Testing effectiveness (Phase 2)Study completedNCT00260689
What this trial is testing

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

Who this might be right for
ImmunosuppresionThrombocytopeniaPancytopenia+1 more
National Heart, Lung, and Blood Institute (NHLBI) 136
Early research (Phase 1)Active Not RecruitingNCT05384756
What this trial is testing

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Who this might be right for
Sickle Cell Disease
City of Hope Medical Center 20
Testing effectiveness (Phase 2)Study completedNCT00089349
What this trial is testing

Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Childhood Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Study completedNCT00276809
What this trial is testing

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
German CLL Study Group 30
Testing effectiveness (Phase 2)Ended earlyNCT00069992
What this trial is testing

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes
Baylor College of Medicine 7
Testing effectiveness (Phase 2)Study completedNCT00278213
What this trial is testing

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Who this might be right for
Prolymphocytic Leukemia
German CLL Study Group 17
Next Page